If you are planning prostate cancer surgery, you may hear about both standard nerve-sparing surgery and the NeuroSAFE technique. Both approaches aim to preserve the nerves involved in erections whenever it is safe to do so. The main difference is how your surgeon decides whether nerve preservation is appropriate during the operation.
Standard nerve-sparing surgery relies on pre-operative information, including MRI, biopsy and PSA results, together with anatomy, operative findings and surgical judgement. NeuroSAFE adds an extra layer of information by using rapid frozen-section pathology during the operation. This allows your surgeon to assess whether cancer is present at the margin closest to the nerve bundles.
This distinction is important because the nerves lie very close to the prostate, and cancer may sometimes be located in the same area. NeuroSAFE may help your surgeon preserve more nerve tissue when it appears safe, while still allowing additional tissue to be removed if cancer is found at the surgical edge. The aim is to achieve the best possible balance between cancer control and functional preservation.
Standard nerve-sparing surgery and NeuroSAFE-guided surgery are not entirely separate operations. NeuroSAFE is an additional intraoperative pathology process used alongside radical prostatectomy to help determine whether initially preserved nerve-adjacent tissue can safely remain.
What Is Standard Nerve-Sparing Surgery?
Standard nerve-sparing prostate surgery is an established technique used during radical prostatectomy. The aim is to preserve one or both neurovascular bundles alongside the prostate when this can be done safely. If you are considering surgery, this approach may improve the likelihood of erectile-function recovery after surgery while still focusing on effective cancer treatment.
The decision to preserve the nerves is based on several factors. These include your PSA level, biopsy results, MRI findings, examination findings, cancer location, baseline erectile function and the surgeon’s experience. Your surgeon uses this information to assess whether nerve-sparing is appropriate in your case.
Standard nerve-sparing surgery remains an established and appropriate option for carefully selected patients. Its functional and oncological outcomes depend on factors including cancer characteristics, baseline function, surgical technique and the extent of nerve preservation. The availability of NeuroSAFE does not mean that standard nerve-sparing surgery is automatically a less effective option.
What Is the NeuroSAFE Technique?
NeuroSAFE stands for neurovascular structure-adjacent frozen-section examination. It is a technique used during prostate cancer surgery to assess the surgical margin next to the nerve bundles while the operation is still underway. If you are considering nerve-sparing surgery, NeuroSAFE provides your surgeon with additional information at a critical stage of the procedure.
After the prostate has been removed, the surface of the prostate specimen adjacent to the neurovascular bundles is rapidly processed and examined by a pathologist. The tissue is frozen, sliced into thin sections, stained, and examined under a microscope. This allows your surgeon to receive important pathology results before the operation is completed.
During NeuroSAFE-guided surgery, the nerve bundle on the assessed side is initially preserved where this is considered technically and oncologically appropriate. The nerve-adjacent surface of the removed prostate is then examined before the operation is completed. If the frozen section is clear, no secondary resection may be required on that side. If cancer reaches the assessed margin, your surgeon may remove additional tissue, which can include part or all of the nerve bundle on that side.
The Main Difference Between the Two Approaches
The main difference between standard nerve-sparing surgery and NeuroSAFE is the information available during the operation. Standard nerve-sparing relies on findings from scans, biopsies, clinical assessment, and surgical judgement. While these tools are valuable, they do not usually provide immediate microscopic assessment of the surgical margin.
NeuroSAFE adds an extra step by introducing intraoperative pathology. During the operation, tissue close to the nerve bundles is examined to determine whether cancer reaches the surgical edge. This gives your surgeon real-time information that is not available with the standard approach.
As a result, the operation can become more adaptable. Instead of relying solely on pre-operative predictions, your surgeon can adjust the nerve-sparing plan based on what the pathologist finds during surgery. This may help support more precise decisions about nerve preservation and cancer control.
NeuroSAFE-Guided vs Standard Nerve-Sparing Surgery
| Feature | Standard nerve-sparing RARP | NeuroSAFE-guided RARP |
| Pre-operative planning | MRI, biopsy, PSA, clinical assessment and surgeon judgement | The same pre-operative planning is required |
| Initial nerve-sparing approach | Based on the planned dissection and intraoperative findings | Usually begins with the planned nerve-sparing dissection |
| Frozen-section pathology | Not routinely used | The nerve-adjacent surface of the removed prostate is examined during surgery |
| When margin information becomes available | Usually with the final pathology report after surgery | Preliminary nerve-adjacent margin information is available during surgery |
| If the assessed margin is clear | The result is generally not known during surgery | No secondary resection may be required from that side |
| If the assessed margin is positive | The result is reviewed after surgery alongside the complete pathology report and subsequent PSA results | Immediate secondary tissue removal may be performed |
| Bilateral nerve-sparing in the NeuroSAFE PROOF trial | Approximately 56% | Approximately 82% |
| Twelve-month erectile-function score in the trial | Mean IIEF-5 score 9.7 | Mean IIEF-5 score 12.7 |
| Six-month continence | No significant difference between groups | No significant difference between groups |
| Operating time | Generally shorter | Usually longer because of tissue processing and pathology |
| Availability | Widely used surgical approach | Requires an experienced surgical team and specialist frozen-section pathology service |
| Final pathology | Required | Still required |
Trial context:
The NeuroSAFE PROOF trial included men with non-metastatic prostate cancer who were suitable for robotic prostatectomy and had good erectile function before surgery without medical assistance. The figures shown are group averages and should not be interpreted as predicted results for every patient.
Why Nerve-Sparing Decisions Are Difficult
The neurovascular bundles lie very close to the outer surface of the prostate. These structures play an important role in erectile function, but cancer can sometimes develop near the same area. If you are considering prostate cancer surgery, this close relationship is one reason nerve-sparing decisions can be challenging.
If too much tissue is removed, your chances of erectile recovery may be reduced. If too little tissue is removed near the cancer, there may be concern about leaving cancer cells behind. Your surgeon must carefully balance these competing priorities during the operation.
This is why nerve-sparing is always a careful judgement rather than a simple choice. The aim is to preserve your nerve function whenever it is safe to do so, without compromising effective cancer removal. Achieving the right balance is one of the most important parts of prostate cancer surgery.
How Standard Nerve-Sparing Decisions Are Made
In standard nerve-sparing surgery, your surgeon plans the procedure using all available information before the operation. This includes MRI findings, biopsy results, PSA levels, and other clinical assessments. Together, these details help determine whether preserving the nerves is likely to be safe.
During the operation, your surgeon also relies on visual assessment, anatomical landmarks, tissue planes, and surgical experience. If you are having robotic surgery, the magnified view can help with precise dissection around the prostate. These factors play an important role in guiding nerve-sparing decisions.
However, microscopic cancer cells at the surgical edge cannot always be identified by sight alone. Even with careful planning and surgical expertise, some details are only visible under a microscope. This is one of the key limitations that the NeuroSAFE technique is designed to address.
How NeuroSAFE Changes the Decision Process
NeuroSAFE changes the decision-making process by providing rapid pathology feedback during the operation. Instead of waiting for the final pathology report after surgery, your surgeon receives important information while the procedure is still taking place. This allows decisions to be based on real-time findings.
The pathologist examines tissue from the prostate surface closest to the nerve bundle and checks whether cancer is present at the surgical margin. The result helps your surgeon decide whether the preserved nerve area appears safe or whether additional tissue should be removed. This information can guide the operation at a critical stage.
The technique can be particularly helpful when the pre-operative plan is not completely straightforward. If you have cancer close to the nerve bundles, NeuroSAFE may provide greater confidence about the safest approach. It aims to reduce both unnecessary nerve removal and the risk of preserving nerves when cancer cells reach the margin.
What Is a Surgical Margin?
A surgical margin is the cut surface of tissue removed during an operation. If cancer cells are present at that surface, it is called a positive surgical margin. If you are discussing pathology results with your surgeon, margin status is one of the important factors that will be reviewed.
A positive surgical margin does not automatically mean that cancer will return. However, it may influence how closely your PSA levels are monitored after surgery and whether any additional treatment is considered. Your healthcare team will assess these findings alongside other pathology results.
NeuroSAFE focuses on the margin closest to the neurovascular bundles. This is the area where preserving your nerve function and achieving effective cancer control can sometimes come into conflict. By assessing this margin during surgery, NeuroSAFE helps guide decisions about nerve preservation in real time.
Why Standard Nerve-Sparing Can Still Be Appropriate
Standard nerve-sparing surgery remains appropriate for many men when pre-operative assessment suggests that one or both neurovascular bundles can be preserved with an acceptable risk of extracapsular disease on that side. In these situations, your surgeon may already have sufficient confidence to preserve the nerves based on the information available before and during the operation. Many men achieve good outcomes with this established approach.
Guideline-based care recognises that nerve-sparing decisions should be made when they are oncologically appropriate. Your surgeon will consider factors such as PSA level, biopsy findings, MRI results, baseline erectile function, cancer location, and your personal priorities before recommending a treatment plan.
This means standard nerve-sparing remains an important and valid surgical technique. NeuroSAFE is designed to provide additional information in selected cases, but it does not replace careful planning or surgical expertise. The quality of the decision still depends on the overall assessment of your individual situation.
Guidance Note
NICE recommends informed and shared treatment decisions, including discussion of the possible effects of prostate cancer treatment on sexual function, continence and quality of life. It advises commissioners to consider robotic surgery for localised prostate cancer and to base robotic systems in centres expected to perform at least 150 robot-assisted radical prostatectomies each year. NICE NG131 does not currently make a specific recommendation on NeuroSAFE.
When NeuroSAFE May Add the Most Value
NeuroSAFE may be particularly relevant when intraoperative margin information could change the extent of nerve preservation. This may include situations where nerve-sparing appears possible but the safest dissection plane is uncertain.
Your surgeon may want to preserve as much nerve tissue as possible while still maintaining effective cancer control. NeuroSAFE adds real-time pathology information during the operation, helping to clarify whether the margin at the nerves appears clear of cancer. This can support more confident decision-making.
Because of this, NeuroSAFE may be considered in selected cases where the result is reasonably likely to influence the operation. It allows your surgeon to tailor the degree of nerve preservation on each side of the prostate based on findings from the operation itself. For you, this may help achieve a better balance between functional recovery and cancer treatment.
What Happens If NeuroSAFE Shows a Clear Margin?
If the frozen section shows no cancer cells at the nerve-adjacent surgical margin, no secondary resection may be required from that side. This allows the nerve-adjacent tissue preserved during the initial dissection to remain in place.
A clear frozen-section result applies only to the margins examined during the operation. It does not replace the detailed final examination of the prostate and any additional tissue removed.
After surgery, your final pathology report and PSA results remain essential for assessing cancer stage, margin status and the need for further follow-up.
What Happens If NeuroSAFE Shows Cancer at the Margin?
If NeuroSAFE identifies cancer at the margin next to a nerve bundle, your surgeon can remove additional tissue from that side during the same operation. This step is sometimes known as a secondary resection. The aim is to improve cancer clearance while the procedure is still underway.
Without NeuroSAFE, this information may not become available until the final pathology report is completed after surgery. By providing real-time feedback, the technique allows your surgeon to respond immediately to findings at the surgical margin. This can help guide treatment decisions at a critical point in the operation.
In some cases, this may reduce the amount of nerve tissue that can be preserved on that side. If you are considering NeuroSAFE, your surgeon should explain beforehand that the technique may either support nerve-sparing or lead to wider tissue removal if cancer control requires it. Achieving effective cancer removal remains the priority throughout the procedure.
How the Two Approaches Affect Erectile Function
Both standard nerve-sparing surgery and NeuroSAFE aim to protect erectile function whenever it is safe to do so. The key difference is that NeuroSAFE provides your surgeon with additional information during the operation, which may support more confident nerve preservation in selected patients. This can be particularly helpful when the decision is not straightforward.
A multicentre randomised phase 3 trial involving men with good erectile function before surgery found that NeuroSAFE-guided robotic prostatectomy resulted in better average patient-reported erectile-function scores at 12 months than standard robotic prostatectomy. The study also reported better short-term urinary continence outcomes at three months, with no serious adverse events or deaths attributed to the NeuroSAFE intervention. If you are considering surgery, these findings provide encouraging evidence for the technique.
However, NeuroSAFE does not guarantee the return of erections after surgery. Your recovery will still depend on factors such as age, baseline erectile function, overall health, nerve preservation, healing, and rehabilitation. While NeuroSAFE may improve the conditions for recovery, individual outcomes can vary considerably.
Why Baseline Erectile Function Matters
Your erectile function before surgery is one of the strongest predictors of recovery afterwards. If you have good erections before treatment, preserving the neurovascular bundles may offer greater potential for maintaining function after surgery. This is why your baseline function is an important part of the pre-operative assessment.
If your erections are already reduced before surgery, nerve-sparing may still be considered when it is safe to do so. However, your recovery expectations may be different, as NeuroSAFE cannot reverse all of the underlying causes of erectile dysfunction. The technique can help guide safe nerve preservation, but it is only one part of the overall picture.
Guidance from the European Association of Urology highlights several factors that influence erectile recovery after prostate cancer treatment. These include age, baseline erectile function, surgical experience, and the ability to preserve the neurovascular bundles. If you are discussing expected outcomes with your surgeon, all of these factors should be considered together.
How the Two Approaches Affect Cancer Control
Cancer control is the first priority in both standard nerve-sparing and NeuroSAFE-guided surgery. If you are considering either approach, it is important to understand that nerves should only be preserved when it is safe to do so. Your surgeon will always focus on removing the cancer effectively.
NeuroSAFE differs because it provides immediate information about the surgical margin beside the nerves. If cancer is found at the margin, your surgeon can remove additional tissue during the same operation. This helps guide decisions based on real-time findings rather than prediction alone.
Observational studies and a 2025 systematic review have generally reported higher nerve-sparing rates, a lower overall risk of positive surgical margins and no significant difference in two-year biochemical recurrence with NeuroSAFE. However, the evidence review noted substantial heterogeneity, possible selection bias and an overall weak evidence base.
In the NeuroSAFE PROOF randomised trial, early oncological measures did not establish the long-term superiority or equivalence of either approach. At 12 months, PSA persistence or biochemical recurrence was reported in 9% of the NeuroSAFE group and 6% of the standard-surgery group, while freedom from recurrence or additional treatment was 86% and 93%, respectively. These short-term findings should not be interpreted as proof of a cancer-control difference because the trial was designed primarily around functional outcomes and longer follow-up is continuing.
Does NeuroSAFE Mean More Nerves Are Preserved?
Many studies have found that NeuroSAFE is associated with higher rates of nerve-sparing surgery. This may involve unilateral nerve-sparing, where one nerve bundle is preserved, or bilateral nerve-sparing, where both bundles are preserved. If you are suitable for nerve-sparing surgery, NeuroSAFE may increase the opportunity to preserve nerve tissue safely.
A validation study reported that standardised intraoperative frozen-section assessment with NeuroSAFE significantly increased nerve-sparing rates without compromising important cancer outcomes in that patient group. The additional pathology information can help your surgeon make more confident decisions during the operation.
However, this does not mean that more nerves will be preserved in every case. If NeuroSAFE detects cancer at the surgical margin, your surgeon may need to remove additional tissue instead. In these situations, cancer control remains the most important consideration.
Bilateral Nerve-Sparing Compared With Unilateral Nerve-Sparing
Bilateral nerve-sparing means preserving the neurovascular bundles on both sides of the prostate. When this can be done safely, it may offer the best opportunity for erectile recovery after surgery. If you are suitable for bilateral nerve-sparing, more of the nerve tissue involved in erections can be protected.
Unilateral nerve-sparing involves preserving one nerve bundle while removing more tissue on the opposite side. This approach may be recommended when the cancer is located closer to one side of the prostate. Your surgeon will decide which option is safest based on your cancer characteristics.
NeuroSAFE can help assess each side of the prostate separately during the operation. This side-specific information may allow your surgeon to preserve one side, both sides, or neither side depending on the margin findings. The aim is to tailor nerve preservation to your individual situation while maintaining cancer control.
Why Side-Specific Assessment Matters
Prostate cancer is often not distributed evenly throughout the prostate. One side of the gland may contain more cancer, or the tumour may be located closer to a nerve bundle on one side than the other. This means the surgical risks can vary between the left and right sides.
Standard nerve-sparing surgery can be planned differently for each side when needed. However, NeuroSAFE adds a microscopic assessment of the tissue next to the nerve bundles during the operation. This provides more detailed information and helps make side-specific decisions more precise.
For you, this means the surgical approach can be tailored to the actual pattern of your cancer. Your surgeon does not need to treat both sides of the prostate in exactly the same way if the risks are different. This may help maximise nerve preservation while maintaining effective cancer control.
How MRI Fits Into Both Approaches
MRI plays an important role in both standard nerve-sparing surgery and NeuroSAFE-guided surgery. If you are preparing for prostate cancer surgery, MRI helps your surgeon assess the location of the tumour, understand the anatomy of the prostate, and evaluate whether the cancer appears close to the outer edge of the gland. This information is used to help plan your operation.
In standard nerve-sparing surgery, MRI findings help guide decisions before the procedure takes place. In NeuroSAFE surgery, MRI still plays a key role in planning, but your surgeon also receives additional information from frozen-section analysis during the operation. This gives your surgical team more information when important decisions need to be made.
Although MRI is highly useful, it cannot show every microscopic detail at the surgical margin. This means some small areas of cancer may not be visible before surgery, even when you have detailed imaging. NeuroSAFE helps address this limitation by examining tissue next to the nerve bundles while you are still in theatre.
How Biopsy Results Fit Into Both Approaches
Biopsy results provide information about the grade of cancer, the amount found in the sampled cores and the areas from which those cores were taken. They help estimate disease extent but cannot map every focus of cancer within the prostate. If you are considering prostate cancer surgery, this information helps your surgeon assess whether nerve-sparing is likely to be safe. It is one of the most important factors used when planning treatment.
In standard nerve-sparing surgery, biopsy findings help guide decisions about whether the nerves can be preserved and on which side. In NeuroSAFE surgery, biopsy results still play a key role because they help your surgeon decide whether frozen-section assessment is likely to provide useful additional information. This allows the surgical plan to be tailored more accurately to your cancer.
A higher-grade or higher-volume tumour may require a more cautious approach. Your surgeon may need to prioritise wider cancer removal if there is a greater risk of the disease extending beyond the prostate. NeuroSAFE can support these decisions, but it does not make unsafe nerve-sparing appropriate.
Does NeuroSAFE Replace Surgical Skill?
No, NeuroSAFE does not replace surgical skill or clinical judgement. Your surgeon still needs to carefully assess the cancer, perform precise dissection, and decide how best to balance cancer control with nerve preservation. The frozen-section result is an additional source of information, not a substitute for experience.
Modern robotic surgery provides magnified vision and highly precise instrument movement. However, the success of the operation still depends on your surgeon’s ability to interpret findings and make appropriate decisions during the procedure. NeuroSAFE supports this decision-making process by providing real-time pathology information.
Experience remains an important factor when using the NeuroSAFE technique. Your surgeon and the pathology team must work closely together to ensure results are assessed accurately and efficiently. This coordinated approach helps you benefit from both surgical expertise and immediate pathological feedback.
Why the Pathology Team Is Central to NeuroSAFE
Standard nerve-sparing surgery usually does not require frozen-section pathology during the operation. NeuroSAFE is different because it relies on rapid assessment of the nerve-adjacent surfaces of the removed prostate specimen. This information helps guide important decisions while surgery is still taking place.
The pathologist must process and examine the tissue quickly and accurately to provide reliable results. At the same time, your surgeon must carefully orientate the specimen so that the correct margin is assessed. Both steps are essential for ensuring that the findings can be interpreted correctly.
This makes NeuroSAFE a highly collaborative technique. Success depends on close coordination between your surgeon, the pathology team, and the operating theatre staff. Clear communication and specialist expertise help ensure that you receive accurate real-time information during surgery.
Does NeuroSAFE Make Surgery Longer?
NeuroSAFE can add some time to a prostate cancer operation because tissue must be frozen, sectioned, stained, examined, and reported while surgery is still underway. The amount of extra time varies between hospitals and depends on how the surgical and pathology teams work together. In most cases, this additional step is carefully planned as part of the procedure.
For selected patients, the extra time may be worthwhile if it helps preserve nerves safely or identifies the need for additional tissue removal. This real-time information can support more precise surgical decision-making when important choices need to be made. However, NeuroSAFE is not usually used if it is unlikely to influence the operation.
Your surgeon should explain whether NeuroSAFE is likely to provide meaningful benefits in your case. The decision will depend on factors such as the location of your cancer, the planned surgical approach, and your functional priorities after treatment. This helps ensure that the technique is used when it is most likely to add value.
What Are the Limitations of Standard Nerve-Sparing?
The main limitation of standard nerve-sparing surgery is that your surgeon cannot always determine whether microscopic cancer has reached the nerve-adjacent margin during the operation. Decisions must be based on the information available before and during surgery. While this approach is effective, some uncertainty can remain.
Pre-operative MRI scans and biopsy results provide valuable guidance when planning treatment. However, these tests cannot identify every microscopic area of cancer or show exactly how close cancer cells may be to the surface of the prostate. This can make nerve-sparing decisions more challenging in certain cases.
As a result, your surgeon may sometimes choose to remove a wider area of tissue to reduce the risk of leaving cancer behind. This approach can support cancer control, but it may also reduce the opportunity to preserve nearby nerves. For you, this could affect the likelihood of maintaining erectile function after surgery.
What Are the Limitations of NeuroSAFE?
NeuroSAFE offers important advantages, but it also has limitations. The technique requires specialist pathology support, careful tissue handling, and close coordination between the surgical and pathology teams. Not every hospital has the resources or expertise needed to provide it routinely.
Frozen-section analysis is designed to answer a specific question during the operation. It helps your surgeon assess whether cancer is present at the nerve-adjacent margin, but it does not replace the detailed final pathology report. You will still need ongoing follow-up, including PSA testing, after surgery.
Although the evidence supporting NeuroSAFE is encouraging, patient selection remains important. The technique may not be suitable or beneficial for every individual undergoing prostate cancer surgery. It is also important to understand that NeuroSAFE cannot guarantee preserved erectile function, negative surgical margins, or a cure for cancer.
Is NeuroSAFE Suitable for Everyone?
No, NeuroSAFE is not suitable or necessary for every patient undergoing prostate cancer surgery. If your cancer appears to be well away from the nerve bundles, the pre-operative assessment and findings during surgery may provide sufficient confidence to proceed with standard nerve-sparing without NeuroSAFE. In these cases, NeuroSAFE may be unlikely to change the surgical plan.
There are also situations where the cancer appears to be very close to the nerves or extends beyond the prostate. If wider tissue removal is clearly required, NeuroSAFE may not alter the safest approach. In this situation, preserving the nerves could increase the risk of leaving cancer behind.
The technique is often most useful when nerve-sparing seems possible but there is some uncertainty about the risk. NeuroSAFE can provide additional information during surgery to help guide decision-making. Your surgeon should explain where your situation falls on this spectrum and whether the technique is likely to offer meaningful benefits.
What If the Cancer Is Higher Risk?
Higher-risk prostate cancer can sometimes require a wider area of tissue to be removed during surgery. This approach helps reduce the risk of leaving cancer behind, but it may limit how much nerve-sparing can be performed safely. As a result, preserving the nerves may be more challenging in these situations.
NeuroSAFE may still be considered in selected higher-risk cases. However, your surgeon must interpret the findings carefully and balance the potential benefits of nerve preservation against the need for effective cancer control. The presence of more aggressive cancer features often leads to a more cautious surgical approach.
The most important question is not simply whether NeuroSAFE is available. Instead, your surgeon must determine whether preserving the nerves is oncologically appropriate for your specific cancer. This decision should be based on your cancer characteristics, imaging findings, and overall treatment goals.
How the Two Approaches Affect Recovery Expectations
Recovery after standard nerve-sparing surgery and NeuroSAFE-guided surgery depends on several factors. These include your continence and erectile function before treatment, your age, general health, the location of the cancer, and how much nerve tissue can be preserved. Every patient’s recovery experience is different.
In selected men, NeuroSAFE may increase the opportunity to preserve nerve tissue safely during surgery. This may support better erectile function recovery compared with a more extensive nerve resection. However, recovery is still a gradual process and may involve rehabilitation, medication, or other supportive treatments.
It is important that you have realistic expectations about recovery after prostate cancer surgery. Your surgeon should provide an honest assessment based on your individual circumstances rather than making guarantees. Even when nerve preservation is successful, erections may take many months or sometimes longer to recover.
What About Urinary Continence?
NeuroSAFE is most often discussed in relation to nerve preservation and erectile function. However, recovery after prostate cancer surgery also involves regaining urinary control. For many men, continence recovery is an important part of returning to normal daily activities.
Research from the NeuroSAFE PROOF trial reported better urinary continence scores at three months after surgery. However, there was no significant difference between the groups at six months. This suggests that any continence benefit may be most noticeable during the early stages of recovery.
It is important to remember that continence recovery depends on many factors beyond the use of NeuroSAFE. These include your anatomy, surgical technique, pelvic floor muscle strength, age, bladder function, and healing after surgery. Your recovery timeline will depend on your individual circumstances as well as the procedure itself.
Choosing Between NeuroSAFE and Standard Nerve-Sparing
The choice between NeuroSAFE and standard nerve-sparing surgery is not simply a matter of choosing an older technique or a newer one. Standard nerve-sparing remains an appropriate option for many men with prostate cancer. NeuroSAFE may offer additional benefits when real-time margin assessment could influence decisions during the operation.
The main difference is that NeuroSAFE provides your surgeon with immediate pathology information from tissue close to the nerve bundles. This allows important surgical decisions to be guided by findings obtained while the procedure is still taking place. For some patients, this extra information can be valuable when the safety of nerve preservation is uncertain.
For selected men, NeuroSAFE may help preserve function more safely while maintaining a strong focus on cancer control. However, the most appropriate approach will depend on your individual cancer characteristics and surgical goals. Your surgeon can explain which option is best suited to your situation.
Key Takeaways
- Standard nerve-sparing and NeuroSAFE-guided surgery use the same essential radical prostatectomy principles.
- NeuroSAFE adds rapid examination of the nerve-adjacent surface of the removed prostate.
- A clear frozen section may allow the initially preserved tissue to remain.
- A positive frozen section may lead to an immediate secondary resection.
- The NeuroSAFE PROOF trial found higher bilateral nerve-sparing rates and better erectile-function scores at 12 months.
- A short-term continence difference was present at three months but not six months.
- Long-term oncological equivalence between NeuroSAFE-guided and standard surgery has not yet been established through randomised evidence.
- Standard nerve-sparing remains an established and appropriate option for many carefully selected patients.
- NeuroSAFE requires specialist pathology support and is not available at every centre.
FAQs:
1. Is NeuroSAFE better than standard nerve-sparing surgery?
NeuroSAFE is not automatically better for every patient. It provides additional real-time pathology information during surgery, which may help guide nerve-sparing decisions in selected cases where the safest approach is uncertain.
2. What is the biggest advantage of NeuroSAFE?
The main advantage of NeuroSAFE is that it allows the nerve-adjacent surgical margin of the removed prostate to be assessed while the operation is still taking place. This can help the surgeon preserve nerves more confidently when cancer does not appear to extend to that area.
3. Does NeuroSAFE reduce the risk of positive surgical margins?
Observational studies and a systematic review have reported a lower overall risk of positive surgical margins with NeuroSAFE. However, the studies were heterogeneous, most were non-randomised and the randomised trial was not designed to prove superior long-term cancer control.
4. Can standard nerve-sparing surgery still preserve erectile function?
Yes, standard nerve-sparing surgery can preserve erectile function when the nerves can be safely spared. Recovery depends on factors such as age, baseline erectile function, overall health and the extent of nerve preservation achieved.
5. Does NeuroSAFE guarantee that both nerve bundles can be preserved?
No, NeuroSAFE does not guarantee bilateral nerve-sparing. If cancer cells reach the nerve-adjacent surgical margin, the surgeon may need to perform an immediate secondary resection from that side.
6. Will NeuroSAFE change the final pathology results?
No. NeuroSAFE provides a rapid assessment of selected nerve-adjacent margins during surgery. If the result is positive, additional tissue may be removed and sent for examination. The prostate and all relevant specimens still undergo detailed permanent-section pathology after the operation.
7. Is NeuroSAFE available at all hospitals?
No, NeuroSAFE requires specialised pathology support and a coordinated surgical team, so it is not available at every centre. Availability varies depending on local expertise and resources.
8. Does NeuroSAFE increase the length of surgery?
NeuroSAFE can add some time to the procedure because specimen margins need to be processed and examined during the operation. The exact additional time depends on the hospital’s pathology workflow and surgical protocols.
9. Can men with higher-risk prostate cancer have NeuroSAFE?
Some men with higher-risk prostate cancer may still be considered for NeuroSAFE, but suitability depends on the location and extent of the cancer. The priority remains complete cancer removal, and nerve preservation is only considered when it is oncologically safe.
10. How do surgeons decide whether NeuroSAFE is appropriate?
The decision is based on factors such as MRI findings, biopsy results, PSA levels, tumour location and your treatment goals. Your surgeon will assess whether real-time margin assessment is likely to influence the surgical plan and improve decision-making in your specific case.
Final Thoughts: NeuroSAFE vs Standard Nerve-Sparing Surgery
Standard nerve-sparing surgery and NeuroSAFE-guided surgery both aim to preserve the neurovascular bundles when this is oncologically appropriate. NeuroSAFE differs by adding rapid examination of the nerve-adjacent margins of the removed prostate while the operation is still taking place.
The NeuroSAFE PROOF trial found higher bilateral nerve-sparing rates and better erectile-function scores at 12 months among men who had good erectile function before surgery. However, NeuroSAFE does not guarantee recovery, and longer follow-up is needed to establish its long-term cancer-control outcomes.
If you are considering NeuroSAFE prostate surgery in London, your consultation should include a personalised review of your MRI, biopsy findings, cancer location, baseline erectile function and the likelihood that intraoperative margin assessment would change the surgical plan.
References:
- Dinneen, E. et al. (2025) ‘Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial’, The Lancet Oncology, 26(4), pp. 447–458. Available at: https://pubmed.ncbi.nlm.nih.gov/40147459/
- Kroon, L.J. et al. (2025) ‘Neurovascular structure-adjacent frozen-section examination during radical prostatectomy: A systematic review and meta-analysis’, European Urology Oncology, 8(5), pp. 1365–1374. Available at: https://www.sciencedirect.com/science/article/pii/S2588931124002906
- van der Slot, M.A. et al. (2022) ‘NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome’, BJU International, 130(5), pp. 628–636. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9796592/
- Schlomm, T. et al. (2012) ‘Neurovascular structure-adjacent frozen-section examination increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients’, European Urology, 62(2), pp. 333–340. Available at: https://pubmed.ncbi.nlm.nih.gov/22591631/
- European Association of Urology (2026) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: Treatment. Arnhem: EAU Guidelines Office. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
- National Institute for Health and Care Excellence (NICE) (2019, last updated 2021; reviewed 2025) Prostate cancer: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng131
- Shaw, G.L. and Almeida-Magana, R. (2026) ‘Clarification of methodology and findings from the NeuroSAFE PROOF randomised controlled trial’, Translational Andrology and Urology, 15(1), p. 31. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12877673/